1. Home
  2. MVST vs IPHA Comparison

MVST vs IPHA Comparison

Compare MVST & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Microvast Holdings Inc.

MVST

Microvast Holdings Inc.

HOLD

Current Price

$1.24

Market Cap

987.8M

Sector

Miscellaneous

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.81

Market Cap

189.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MVST
IPHA
Founded
2006
1999
Country
United States
France
Employees
N/A
163
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
987.8M
189.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MVST
IPHA
Price
$1.24
$1.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$6.00
$5.75
AVG Volume (30 Days)
5.5M
135.0K
Earning Date
05-11-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$24.55
$180.36
Revenue Next Year
$17.08
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.17
$1.18
52 Week High
$7.12
$2.63

Technical Indicators

Market Signals
Indicator
MVST
IPHA
Relative Strength Index (RSI) 37.62 51.54
Support Level $1.17 $1.69
Resistance Level $2.16 $1.84
Average True Range (ATR) 0.13 0.13
MACD -0.00 -0.02
Stochastic Oscillator 12.40 9.90

Price Performance

Historical Comparison
MVST
IPHA

About MVST Microvast Holdings Inc.

Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: